Syndax Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/25
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should KnowZacks Investment Research • 07/29/25
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025GlobeNewsWire • 07/28/25
Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug ApprovalsSeeking Alpha • 07/08/25
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid LeukemiaGlobeNewsWire • 06/24/25
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025GlobeNewsWire • 06/12/25
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025GlobeNewsWire • 06/12/25
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)GlobeNewsWire • 05/14/25
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical OfficerGlobeNewsWire • 05/12/25
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?Zacks Investment Research • 05/09/25
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal BloodGlobeNewsWire • 05/07/25
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/05/25
Syndax Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/05/25
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025GlobeNewsWire • 04/28/25
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology ForumGlobeNewsWire • 04/02/25
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/03/25
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 03/03/25
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025GlobeNewsWire • 02/24/25
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmGlobeNewsWire • 02/10/25